Literature DB >> 5813121

Permeability-increasing activity in hereditary angioneurotic edema plasma. II. Mechanism of formation and partial characterization.

V H Donaldson, O D Ratnoff, W Dias Da Silva, F S Rosen.   

Abstract

Plasma from persons with hereditary angioneurotic edema readily developed the capacity to increase vascular permeability and to induce the isolated rat uterus to contract. Both activities resided in a small, heat-stable molecule that was apparently a polypeptide. Crude preparations of the polypeptide were inactivated during incubation with trypsin. They also failed to produce pain and erythema, but caused markedly increased vascular permeability in human skin. These characteristics differ from those of bradykinin, from which crude preparations of the polypeptide could also be distinguished by electrophoretic mobility and paper chromatographic behavior. Proof that the polypeptide is truly different from bradykinin must await its further purification. Histamine played no role in the activities observed. Although the enzymes functioning to release the permeability factor and kinin activities in hereditary angioneurotic edema plasma were not clearly defined, one or more plasma enzymes other than C'1 esterase presumably participated either in conjunction with C'1 esterase or in pari passu events to release the polypeptide mediating these activities.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5813121      PMCID: PMC322269          DOI: 10.1172/JCI106022

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  ACTION OF COMPLEMENT IN HEREDITARY ANGIONEUROTIC EDEMA: THE ROLE OF C'1-ESTERASE.

Authors:  V H DONALDSON; F S ROSEN
Journal:  J Clin Invest       Date:  1964-11       Impact factor: 14.808

2.  STUDIES ON PLASMA KININS. II. SOME PROPERTIES OF THE KININ-DESTROYING ENZYME.

Authors:  E BISHOP; J MARGOLIS
Journal:  Aust J Exp Biol Med Sci       Date:  1963-08

3.  [STUDIES ON THE STRUCTURE OF KALLIKREIN INACTIVATOR FROM CATTLE LUNG. I. MOLECULAR WEIGHT, END GROUP ANALYSIS AND AMINO ACID COMPOSITION].

Authors:  F A ANDERER; S HOERNLE
Journal:  Z Naturforsch B       Date:  1965-05       Impact factor: 1.047

4.  Action of the kallikreins on synthetic ester substrates.

Authors:  M E WEBSTER; J V PIERCE
Journal:  Proc Soc Exp Biol Med       Date:  1961-05

5.  Assay and properties of serum inhibitor of C'l-esterase.

Authors:  L R LEVY; I H LEPOW
Journal:  Proc Soc Exp Biol Med       Date:  1959 Aug-Sep

6.  Evidence for the release of bradykinin in carcinoid syndrome.

Authors:  J A Oates; W A Pettinger; R B Doctor
Journal:  J Clin Invest       Date:  1966-02       Impact factor: 14.808

7.  INHIBITION OF beta HEMOLYTIC STREPTOCOCCI FIBRINOLYSIN BY TRYPSIN INHIBITOR (ANTIPROTEASE).

Authors:  I A Mirsky
Journal:  Science       Date:  1944-09-01       Impact factor: 47.728

8.  Complement as a mediator of inflammation. II. Biological properties of anaphylatoxin prepared with purified components of human complement.

Authors:  W Dias Da Silva; I H Lepow
Journal:  J Exp Med       Date:  1967-05-01       Impact factor: 14.307

9.  The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement.

Authors:  C G Cochrane; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-02-01       Impact factor: 14.307

10.  The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor.

Authors:  O D Ratnoff; J Pensky; D Ogston; G B Naff
Journal:  J Exp Med       Date:  1969-02-01       Impact factor: 14.307

View more
  21 in total

Review 1.  The new era of C1-esterase inhibitor deficiency therapy.

Authors:  Louanne Marie Tourangeau; Bruce L Zuraw
Journal:  Curr Allergy Asthma Rep       Date:  2011-10       Impact factor: 4.806

2.  Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients.

Authors:  B L Zuraw; J G Curd
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

3.  Hereditary angioneurotic edema. A case with recurring abdominal pain.

Authors:  P S Kennedy; R K Goyal; T Hersh
Journal:  Am J Dig Dis       Date:  1972-05

4.  Generation of the bioactive kallikrein-derived fragment, C3d-k, by HANE-plasma.

Authors:  T Seya; S Nagasawa; J P Atkinson
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

5.  C1r, subunit of the first complement component: purification, properties, and assay based on its linking role.

Authors:  M M De Bracco; R M Stroud
Journal:  J Clin Invest       Date:  1971-04       Impact factor: 14.808

Review 6.  Acute inflammation. A review.

Authors:  G B Ryan; G Majno
Journal:  Am J Pathol       Date:  1977-01       Impact factor: 4.307

7.  In vitro activation of C1s in plasma of patients with hereditary angioneurotic oedema.

Authors:  S Shafiasghar; R H Cormane; K W Pondman
Journal:  Clin Exp Immunol       Date:  1976-08       Impact factor: 4.330

8.  Response of variant hereditary angioedema phenotypes to danazol therapy. Genetic implications.

Authors:  J E Gadek; S W Hosea; J A Gelfand; M M Frank
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

9.  The pathophysiology of hereditary angioedema.

Authors:  Bruce L Zuraw
Journal:  World Allergy Organ J       Date:  2010-09       Impact factor: 4.084

10.  Hereditary angioneurotic oedema: an unusual cause of recurring abdominal pain.

Authors:  E J Feller; H M Spiro; L A Katz
Journal:  Gut       Date:  1970-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.